SCHEMBL18397902

SCHEMBL18397902

CC(C)(C)OC(=O)NCc1cc(=O)c2cc(C(=O)O)ccc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 7/20 0.44
STS P08842 1/20 0.41
MTNR1A P48039 3/20 0.40
MTNR1B P49286 3/20 0.40
BCHE P06276 1/20 0.40
CNR2 P34972 1/20 0.40
TTR P02766 2/20 0.40
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
CYP2C9 P11712 1/20 0.38
PTGER1 P34995 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
KMT2A Q03164 1/20 0.38
PTGDR Q13258 1/20 0.38
HSD17B10 Q99714 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18397930 0.90 LOXL2 (0.43) LOXL2MTNR1AMTNR1BBCHECNR2
SCHEMBL20438093 0.88 LOXL2 (0.42) LOXL2MTNR1AMTNR1BBCHECNR2
SCHEMBL20438077 0.85 L3MBTL1 (0.43) MTNR1AMTNR1BBCHECNR2KDM4E
SCHEMBL4424912 0.85 TBXAS1 (0.45) MTNR1AMTNR1BKDM4EALDH1A1HPGD
SCHEMBL20438076 0.84 BCHE (0.47) MTNR1AMTNR1BBCHECNR2KDM4E
SCHEMBL20438104 0.84 LOXL2 (0.60) LOXL2CNR2MEN1KMT2AGAA
SCHEMBL20438083 0.84 LOXL2 (0.62) LOXL2CNR2HPGDKMT2A
SCHEMBL20438088 0.82 LOXL2 (0.43) LOXL2MTNR1AMTNR1BBCHECNR2
SCHEMBL20438105 0.82 LOXL2 (0.56) LOXL2MTNR1AMTNR1BCNR2ALDH1A1
SCHEMBL20438095 0.81 MTNR1A (0.45) LOXL2STSMTNR1AMTNR1BBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-08-02 US disclosed
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-08-02 US disclosed
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-08-02 US disclosed
EP-3325462-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2018-05-30 EP disclosed
WO-2017015221-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX LOXL2 1/4885STS 628/4885MTNR1A 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.